Revista nº 802

168 20. Carmagnola D, Celestino S, Abati S. Dental and periodontal history of oncologic patients on parenteral bisphosphonates with or without osteonecrosis of the jaws: A pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod.2008; 106(6):e10-5. 21. Vahtsevanos K, Kyrgidis A, Verrou E, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate- relatedosteonecrosis of the jaw. JClin Oncol. 2009; 27 (32):5356-5362. 22. Dunstan CR, Felsenberg D, SeibelMJ. Therapy insight: The risks and benefits of bisphosphonates for the treatment of tumor- induced bone disease. Nat Clin Pract Oncol. 2007; 4 (1):42-55. 23. Badran, Z; Kraehenmann, MA; Guicheux, J et al. Bisphosphonates in periodontal treatment: a review. Oral Health Prev Dent. 2009; 7(1):3-12. 24. Wehrhan, F; Hyckel, P; Ries, J et al.: Expression of Msx-1 is suppressed in bisphosphonate associated osteonecrosis related jaw tissue-etiopathology considerations respecting jaw developmental biology related unique features. J Translat Med. 2010; 13; 8:96. 25. Hoff, AO; Toth, BB; Altundag, K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008; 23(6):826-836. 26. Kos M. Association of dental and periodontal status with bisphosphonate-related osteonecrosis of the jaws. A retrospective case controlled study. Arch Med Sci. 2014; 10(1):117-23. 27. Mawardi H, Giro G, Kajiya M, et al. A role of oral bacteria in bisphosphonate-induced osteonecrosis of the jaw. J Dent Res. 2011; 90(11) :1339-1345. 28. Nicolau-Galitis, O; Razis, E; Galitis, D et al. Periodontal disease preceding osteonecrosis of the jaw (ONJ) in cáncer patients receiving antiresorptives alone or combined with targeted therapies: report of 5 cases and literature reviw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015; 120 (6): 699-706. 29. Manfredi, M; Mergoni, G; Goldoni, M et al. A 5 – years retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zolendronic acid for bone metastases from solid tumors. Med Oral Patol Oral Cir Bucal. 2017; 1; 22 (3): e 342-8. 30. Krimmel, M; Ripperger, J; Hairass, M et al. Does dental and oral health influence the development and course of bisphosphonate-related osteonecrosis of the jaws (BRONJ)? Oral Maxillofac Surg. 2014; 18(2):213-8. 31. Edwards, BJ; Hellstein, JW; Jacobsen, PL et al. American Dental Association Council on Scientific Affairs Expert Panel on Bisphosphonate-Associated Osteonecrosis of the Jaw.Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: An advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2008; 139 (37):1674- 1677. 32. Hellstein JW, Adler RA, Edwards B, et al; American Dental Association Council on Scientific Affairs Expert Panel on Antiresorptive Agents. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: Executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2011; 142:1243-1251. 33. Nisi, M; La Ferla, F; Karapetsa, D et al. Risk factors influencing BRONJ staging in patient receiving intravenous bisphosphonates: a multivariate analysis. Int J Oral Maxillofaxc Surg.2015; 44 (5): 586-591. 34. Bagán, J; Blade, J; Cozar, JM et al. Recommendations for the prevention, diagnosis and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Patol Oral Cir Bucal. 2007; 12 (4): E336-40.